BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-5. [PMID: 28187980 DOI: 10.1016/j.kint.2016.12.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Koopman JJE, van Essen MF, Rennke HG, de Vries APJ, van Kooten C. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys. Front Immunol 2020;11:599974. [PMID: 33643288 DOI: 10.3389/fimmu.2020.599974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Radhakrishnan J. Anticomplement therapies in "secondary thrombotic microangiopathies": ready for prime time? Kidney Int 2019;96:833-5. [PMID: 31543155 DOI: 10.1016/j.kint.2019.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Nishi K, Sato M, Ogura M, Okutsu M, Ishikura K, Kamei K. Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy. BMC Nephrol 2020;21:323. [PMID: 32746791 DOI: 10.1186/s12882-020-01985-5] [Reference Citation Analysis]
4 Tsui C, Dokouhaki P, Prasad B. Fibrillary Glomerulonephritis with Crescentic and Necrotizing Glomerulonephritis and Concurrent Thrombotic Microangiopathy. Case Rep Nephrol Dial 2018;8:182-91. [PMID: 30320122 DOI: 10.1159/000492529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
6 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Chua JS, Zandbergen M, Wolterbeek R, Baelde HJ, van Es LA, de Fijter JW, Bruijn JA, Bajema IM. Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. Mod Pathol 2019;32:1147-57. [PMID: 30936425 DOI: 10.1038/s41379-019-0259-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
8 Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. Am J Kidney Dis 2019;74:56-72. [PMID: 30851964 DOI: 10.1053/j.ajkd.2018.11.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
9 Neves PDMM, Souza RA, Torres FM, Reis FA, Pinheiro RB, Dias CB, Yu L, Woronik V, Furukawa LS, Cavalcante LB, de Almeida Araújo S, Wanderley DC, Malheiros DM, Jorge LB. Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy. PLoS One 2020;15:e0233199. [PMID: 33147224 DOI: 10.1371/journal.pone.0233199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Cadet B, Meshoyrer D, Kim Z. Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review. Cardiovasc Endocrinol Metab 2021;10:225-30. [PMID: 34765894 DOI: 10.1097/XCE.0000000000000247] [Reference Citation Analysis]
11 Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, Mellmann A, Dittmer R, Jeglitsch M, Haas CS. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 2020;13:208-16. [PMID: 32296526 DOI: 10.1093/ckj/sfz066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hanna RM, Abdelnour L, Zuckerman JE, Ferrey AJ, Pai A, Vahabzadeh K, Wilson J, Torres EA, Kalantar-Zadeh K, Kurtz IB. Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab. SAGE Open Med Case Rep 2020;8:2050313X20952650. [PMID: 32913652 DOI: 10.1177/2050313X20952650] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Reference Citation Analysis]
14 Larsen CP, Wilson JD, Best-Rocha A, Beggs ML, Hennigar RA. Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. Mod Pathol 2018;31:488-94. [PMID: 29148534 DOI: 10.1038/modpathol.2017.154] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
15 Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M. Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1719-32. [PMID: 31694864 DOI: 10.2215/CJN.05830519] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
16 Estrada CC, Cardona S, Guo Y, Revelo MP, D'Agati VD, Koganti S, Devaraj J, He JC, Heeger PS, Mallipattu SK. Endothelial-specific loss of Krüppel-Like Factor 4 triggers complement-mediated endothelial injury. Kidney Int 2022:S0085-2538(22)00344-1. [PMID: 35483525 DOI: 10.1016/j.kint.2022.03.025] [Reference Citation Analysis]
17 Chang A. Thrombotic microangiopathy and the kidney. Diagnostic Histopathology 2017;23:101-8. [DOI: 10.1016/j.mpdhp.2017.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
18 Langlo KAR, Silva GJJ, Overrein TS, Adams V, Wisløff U, Dalen H, Rolim N, Hallan SI. Circulating microRNAs May Serve as Biomarkers for Hypertensive Emergency End-Organ Injuries and Address Underlying Pathways in an Animal Model. Front Cardiovasc Med 2020;7:626699. [PMID: 33644125 DOI: 10.3389/fcvm.2020.626699] [Reference Citation Analysis]
19 Van Laecke S, Van Biesen W. Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? Kidney Int 2017;91:1271-4. [PMID: 28501299 DOI: 10.1016/j.kint.2017.02.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
20 Calvaruso L, Naticchia A, Ferraro PM, Vischini G, Costanzi S. Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report. Case Rep Nephrol 2019;2019:9264824. [PMID: 31360562 DOI: 10.1155/2019/9264824] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Brás AC, Santos AS, Lima A, Costa MV, Carrilho PS, Rodrigues BG. Malignant hypertension and atypical hemolytic uremic syndrome: a possible continuum between two entities? J Hum Hypertens 2022. [PMID: 35082378 DOI: 10.1038/s41371-021-00651-z] [Reference Citation Analysis]
22 Ding J, Qu Z, Yu F. A rare case of malignant hypertension with splenic rupture and thrombotic microangiopathy: A case report. Medicine (Baltimore) 2020;99:e20581. [PMID: 32664062 DOI: 10.1097/MD.0000000000020581] [Reference Citation Analysis]
23 Villafuerte Ledesma HM, Peña Porta JM, Iñigo Gil P, Martin Azara P, Ruiz Lalglesia JE, Tomás LaTorre A, Martínez Burillo A, Vernet Perna P, Álvarez Lipe R. Severe renal failure and thrombotic microangiopathy induced by malignant hypertension successfully treated with spironolactone. Ann Cardiol Angeiol (Paris) 2018;67:208-14. [PMID: 29753419 DOI: 10.1016/j.ancard.2018.04.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 2019;23:65-75. [PMID: 29959568 DOI: 10.1007/s10157-018-1609-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
26 Menendez-Castro C, Cordasic N, Fahlbusch FB, Ekici AB, Kirchner P, Daniel C, Amann K, Velkeen R, Wölfle J, Schiffer M, Hartner A, Hilgers KF. RNA sequencing reveals induction of specific renal inflammatory pathways in a rat model of malignant hypertension. J Mol Med (Berl) 2021;99:1727-40. [PMID: 34528115 DOI: 10.1007/s00109-021-02133-8] [Reference Citation Analysis]
27 van de Lest NA, Zandbergen M, Wolterbeek R, Kreutz R, Trouw LA, Dorresteijn EM, Bruijn JA, Bajema IM, Scharpfenecker M, Chua JS. Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. Kidney Int 2019;96:738-49. [PMID: 31327475 DOI: 10.1016/j.kint.2019.04.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhang Y, Yang C, Zhou X, Hu R, Quan S, Zhou Y, Li Y, Xing G. Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis. Nephrol Dial Transplant 2020:gfaa280. [PMID: 33367879 DOI: 10.1093/ndt/gfaa280] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Halimi J, Thoreau B, von Tokarski F, Bauvois A, Gueguen J, Goin N, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Lemaignen A, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Frémeaux-bacchi V, Vigneau C, Bayer G, Fakhouri F. What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study. BMC Nephrol 2022;23. [DOI: 10.1186/s12882-022-02672-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Patriquin CJ, Pavenski K, Garland J, Girard L, Isenring P. Complement-Amplifying Conditions in Atypical Hemolytic Uremic Syndrome: A Canadian Case Series. Can J Kidney Health Dis 2022;9:205435812211002. [DOI: 10.1177/20543581221100288] [Reference Citation Analysis]
31 Timmermans SAMEG, van Paassen P; Limburg Renal Registry. Mother and Child Reunion in "Hypertensive" End-Stage Renal Disease: Will They Complement Each Other? Nephron 2019;142:253-7. [PMID: 30870849 DOI: 10.1159/000497779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Cavero T, Arjona E, Soto K, Caravaca-fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney International 2019;96:995-1004. [DOI: 10.1016/j.kint.2019.05.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
33 Timmermans SAMEG, Wérion A, Damoiseaux JGMC, Morelle J, Reutelingsperger CP, van Paassen P. Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy. Hypertension 2020;75:422-30. [PMID: 31865800 DOI: 10.1161/HYPERTENSIONAHA.119.13714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
34 Wenzel UO, Bode M, Kurts C, Ehmke H. Salt, inflammation, IL-17 and hypertension. Br J Pharmacol 2019;176:1853-63. [PMID: 29767465 DOI: 10.1111/bph.14359] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
35 Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. J Mol Med (Berl) 2021. [PMID: 34714369 DOI: 10.1007/s00109-021-02102-1] [Reference Citation Analysis]
36 Gallan AJ, Chang A. A New Paradigm for Renal Thrombotic Microangiopathy. Semin Diagn Pathol 2020;37:121-6. [PMID: 32085935 DOI: 10.1053/j.semdp.2020.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Wenzel UO, Kemper C, Bode M. The role of complement in arterial hypertension and hypertensive end organ damage. Br J Pharmacol 2021;178:2849-62. [PMID: 32585035 DOI: 10.1111/bph.15171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Cook HT. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome. Curr Opin Nephrol Hypertens 2018;27:165-70. [PMID: 29517501 DOI: 10.1097/MNH.0000000000000412] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
39 Cserhalmi M, Uzonyi B, Merle NS, Csuka D, Meusburger E, Lhotta K, Prohászka Z, Józsi M. Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R. Front Immunol 2017;8:1800. [PMID: 29321782 DOI: 10.3389/fimmu.2017.01800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Timmermans SAMEG, Damoiseaux JGMC, Werion A, Reutelingsperger CP, Morelle J, van Paassen P. Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes. Kidney Int Rep 2021;6:1099-109. [PMID: 33912760 DOI: 10.1016/j.ekir.2021.01.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Tao J, Lieberman J, Lafayette RA, Kambham N. A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis. BMC Nephrol 2018;19:355. [PMID: 30541482 DOI: 10.1186/s12882-018-1170-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Timmermans SA, van Paassen P. The Authors Reply. Kidney International 2017;92:267-8. [DOI: 10.1016/j.kint.2017.03.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
43 Tsai HM. Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia. Am J Med 2019;132:161-7. [PMID: 30145224 DOI: 10.1016/j.amjmed.2018.08.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
44 Darshan R, Krishnamurthy S, Sivamurukan P, Kumar CGD, Dhayalini R, Gunasekaran D, Narayanan P, Ganesh RN. Anti-Complement Factor H Autoantibody-Associated Atypical Hemolytic Uremic Syndrome. Indian J Pediatr 2020;87:462-3. [PMID: 31713210 DOI: 10.1007/s12098-019-03115-y] [Reference Citation Analysis]
45 Ma H, Jiang M, Fu Z, Wang Z, Shen P, Shi H, Feng X, Chen Y, Ding X, Wu Z, Zhang W. Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study. J Clin Hypertens (Greenwich) 2020;22:914-23. [PMID: 32271999 DOI: 10.1111/jch.13848] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Chen X, Wang Y, Yu X, Wang S, Zhao M. Potential Involvement of Complement Activation in Kidney Vascular Lesions of Arterionephrosclerosis. Front Med 2022;9:836155. [DOI: 10.3389/fmed.2022.836155] [Reference Citation Analysis]
48 Ruderman I, Finlay M, Barbour T. The perfect storm. Kidney International 2017;92:267. [DOI: 10.1016/j.kint.2017.03.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
49 Hanna RM, Ferrey A, Rhee CM, Kalantar-Zadeh K. Renal-Cerebral Pathophysiology: The Interplay Between Chronic Kidney Disease and Cerebrovascular Disease. J Stroke Cerebrovasc Dis 2021;30:105461. [PMID: 33199089 DOI: 10.1016/j.jstrokecerebrovasdis.2020.105461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Hanna R, Zuckerman JE, Ferrey A, Torres EA, Tonthat S, Barsoum M, Ghobry L, Wassef O, Kalantarzadeh K. Finding of pathological thrombomodulin gene variant in a patient with idiopathic nodular glomerulosclerosis and chronic thrombotic microangiopathy-like changes. SAGE Open Med Case Rep 2020;8:2050313X20940510. [PMID: 32699635 DOI: 10.1177/2050313X20940510] [Reference Citation Analysis]
51 Rosa-Guerrero P, Leiva-Cepas F, Agüera-Morales M, Navarro-Cabello MD, Rodríguez-Benot A, Torres-De-Rueda A. First Report in the Literature of Biopsy-Proven Noncollapsing Focal Segmental Glomerulosclerosis Relapse in a Second Renal Transplant Presenting With Thrombotic Microangiopathy: A Case Report. Transplant Proc 2021:S0041-1345(21)00627-8. [PMID: 34627595 DOI: 10.1016/j.transproceed.2021.07.056] [Reference Citation Analysis]
52 Zuckerman JE, Chang A. Complement and Renal Thrombotic Microangiopathy Associated With Hypertension and Scleroderma. Adv Chronic Kidney Dis 2020;27:149-54. [PMID: 32553247 DOI: 10.1053/j.ackd.2019.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
53 Katsuno T, Ito Y, Kagami S, Kitamura H, Maruyama S, Shimizu A, Sugiyama H, Sato H, Yokoyama H, Kashihara N. A nationwide cross-sectional analysis of thrombotic microangiopathy in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 2020;24:789-97. [PMID: 32415379 DOI: 10.1007/s10157-020-01896-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Henry N, Mellaza C, Fage N, Beloncle F, Genevieve F, Legendre G, Orvain C, Garnier AS, Cousin M, Besson V, Subra JF, Duveau A, Augusto JF, Brilland B. Retrospective and Systematic Analysis of Causes and Outcomes of Thrombotic Microangiopathies in Routine Clinical Practice: An 11-Year Study. Front Med (Lausanne) 2021;8:566678. [PMID: 33718396 DOI: 10.3389/fmed.2021.566678] [Reference Citation Analysis]
55 Timmermans SAMEG, Abdul-Hamid MA, Potjewijd J, Theunissen ROMFIH, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. J Am Soc Nephrol 2018;29:2234-43. [PMID: 29858281 DOI: 10.1681/ASN.2018020184] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 8.8] [Reference Citation Analysis]
56 Timmermans SAMEG, Werion A, Spaanderman MEA, Reutelingsperger CP, Damoiseaux JGMC, Morelle J, van Paassen P. The natural course of pregnancies in women with primary atypical haemolytic uraemic syndrome and asymptomatic relatives. Br J Haematol 2020;190:442-9. [PMID: 32342491 DOI: 10.1111/bjh.16626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
58 Haller H. Thrombotische Mikroangiopathie und Niere. Nephrologe 2019;14:100-7. [DOI: 10.1007/s11560-019-0320-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
59 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
60 Wang C, Wang Z, Zhang W. The potential role of complement alternative pathway activation in hypertensive renal damage. Exp Biol Med (Maywood) 2022;:15353702221091986. [PMID: 35473318 DOI: 10.1177/15353702221091986] [Reference Citation Analysis]